留言板

尊敬的读者、作者、审稿人, 关于本刊的投稿、审稿、编辑和出版的任何问题, 您可以本页添加留言。我们将尽快给您答复。谢谢您的支持!

姓名
邮箱
手机号码
标题
留言内容
验证码
x 关闭 永久关闭

应中央军委要求，2022年9月起，《药学实践杂志》将更名为《药学实践与服务》，双月刊，正文96页；2023年1月起，拟出版月刊，正文64页，数据库收录情况与原《药学实践杂志》相同。欢迎作者踊跃投稿！

用于肿瘤治疗的小分子干扰RNA非病毒载体研究进展

王欢,  马志强,  杨峰

downloadPDF
文章导航 > 药学实践与服务  > 2015 >  33(6): 498-501
王欢, 马志强, 杨峰. 用于肿瘤治疗的小分子干扰RNA非病毒载体研究进展[J]. 药学实践与服务, 2015, 33(6): 498-501. doi: 10.3969/j.issn.1006-0111.2015.06.005
引用本文: 王欢, 马志强, 杨峰. 用于肿瘤治疗的小分子干扰RNA非病毒载体研究进展[J]. 药学实践与服务, 2015, 33(6): 498-501. doi: 10.3969/j.issn.1006-0111.2015.06.005
shu
WANG Huan, MA Zhiqiang, YANG Feng. Current status of non-viral siRNA vectors for therapy of cancers[J]. Journal of Pharmaceutical Practice and Service, 2015, 33(6): 498-501. doi: 10.3969/j.issn.1006-0111.2015.06.005
Citation: WANG Huan, MA Zhiqiang, YANG Feng. Current status of non-viral siRNA vectors for therapy of cancers[J]. Journal of Pharmaceutical Practice and Service, 2015, 33(6): 498-501. doi: 10.3969/j.issn.1006-0111.2015.06.005
shu

用于肿瘤治疗的小分子干扰RNA非病毒载体研究进展

doi: 10.3969/j.issn.1006-0111.2015.06.005
  • 1.

    福建中医药大学药学院, 福建 福州 350122

  • 2.

    第二军医大学药学院无机化学教研室, 上海 200433

Current status of non-viral siRNA vectors for therapy of cancers

  • 1.

    School of Pharmacy, Fujian University of Traditional Chinese Medicine, Fuzhou 350122, China

  • 2.

    Department of Inorganic Chemistry, School of Pharmacy, Second Militatry University, Shanghai 200433, China

  • 摘要: 近年来,小分子干扰RNA(siRNA)作为RNA干扰 (RNAi) 技术的效应分子,已被广泛用于恶性肿瘤的基因治疗领域。欲获得理想的治疗效果,其关键因素是寻找一种安全、高效、稳定、可控的基因载体。非病毒载体具有低毒、低免疫原性、制备简单、目的基因容量大、外源基因随机整合率低且携带基因大小类型不受限制等突出优势,已经成为目前siRNA载体的研究热点。在以往学者的研究基础上,从药剂学的角度,笔者对这些载体在siRNA传递系统中的研究现况做回顾性总结。
    Abstract: In the recent years, siRNA has been widely used as effector molecule in the field of gene therapy for cancer. In order to achieve ideal treatment effect, the key factor is to find safe, efficient, stable and controllable gene vectors. The commonly used vectors include viral and non-viral vectors. The non-viral gene vector has superiority of low toxicity, bare immunogenicity, simple to manufacture and high capacity which have been taken as the highlight of the research of carrier of gene drugs. Based on the study of the previous researchers, this study reviewed the prevalence study of the former carriers in the delivery system of siRNA from the point of pharmaceutics.
  • [1] David S, Pitard B, Benoit JP, et al. Non-viral nanosystems for systemic siRNA delivery[J].Pharmacol Res, 2010,62(2): 100-114.
    [2] Tiemann K, Rossi JJ. RNAi-based therapeutics-current status, challenges and prospects[J].EMBO Mol Med, 2009, 1(3): 142-151.
    [3] Liu W, Chen JM. Progress in studies of the structure-activity relationship of cationic lipid-mediated gene delivery[J].Chin J New Drug, 2011,20( 20): 1975-1980.
    [4] Yang ST, Zaitseva E, Chernomordik LV, et al. Cell-penetrating peptide induces leaky fusion of liposomes containing late endosome-specific anionic lipid[J].Biophys J,2010, 99(8): 2525-2533.
    [5] Han SE, Kang H, Shim GY, et al. Novel cationic cholesterol derivative-based liposomes for serum-enhanced delivery of siRNA[J].Int J Pharm, 2008,353(1-2): 260-269.
    [6] Maslov MA, Kabilova TO, Petukhov IA, et al. Novel cholesterol spermine conjugates provide efficient cellular delivery of plasmid DNA and small interfering RNA[J].J Control Release, 2012, 160(2): 182-193
    [7] Kim J, Kim SW, W Kim WJ. PEI-g-PEG-RGD/small interference RNA polyplex-mediated silencing of vascular endothelial growth factor receptor and its potential as an anti-angiogenic tumor therapeutic strategy[J].Oligonucleotides, 2011,21(2): 101-107.
    [8] Malek A, Czubayko F, Aigner A. PEG grafting of polyethylenimine (PEI) exerts different effects on DNA transfection and siRNA-induced gene targeting efficacy[J].J Drug Target, 2008, 16(2): 124-139.
    [9] Xia W, Wang P, Lin C, et al. Bioreducible polyethylenimine-delivered siRNA targeting human telomerase reverse transcriptase inhibits HepG2 cell growth in vitro and in vivo[J].J Control Release, 2012, 157(3): 427-436.
    [10] Yu T, Liu X. Bolcato-Bellemin AL,et al. An amphiphilic dendrimer for effective delivery of small interfering RNA and gene silencing in vitro and in vivo[J].Angew Chem Int Ed Engl, 2012,51(34): 8478-8484.
    [11] Biswas S, Deshpande PP, Navarro GS, et al. Lipid modified triblock PAMAM-based nanocarriers for siRNA drug co-delivery[J].Biomaterials, 2013, 34(4): 1289-12301.
    [12] Perez AP, Mundina-Weilenmann C, Romero EL, et al. Increased brain radioactivity by intranasalP-labeled siRNA dendriplexes within in situ-forming mucoadhesive gels[J].Int J Nanomedicine, 2012, 7: 1373-1385.
    [13] Liu P, Yu H, Sun Y, et al. A mPEG-PLGA-b-PLL copolymer carrier for adriamycin and siRNA delivery[J].Biomaterials, 2012, 33(17): 4403-4412.
    [14] Ambardekar VV, Wakaskar RR, Sharma B, et al. The efficacy of nuclease-resistant Chol-siRNA in primary breast tumors following complexation with PLL-PEG(5K)[J].Biomaterials, 2013.4839-4848.
    [15] Christie RJ, Matsumoto Y, Miyata K, et al. Targeted polymeric micelles for siRNA treatment of experimental cancer by intravenous injection[J].ACS Nano, 2012, 6(6): 5174-5189.
    [16] Mumper RJ, Wang J, Claspel JM, et al. Novel polymeric condensing carriers for gene delivery[J].Symp Controlled Rel,1995, 22:178.
    [17] Zhou SM, Kong FQ, Sun B, et al. Phosphorylatable short peptide conjugated low molecular weight chitosan for efficient siRNA delivery and target gene silencing[J].Chin J Biochem Molecul Biol, 2011, 27(10): 980-986.
    [18] Pezzoli D, Olimpieri F, Malloggi C, et al. Chitosan-graft-branched polyethylenimine copolymers: influence of degree of grafting on transfection behavior[J].PLoS One, 2012, 7(4): e34711.
    [19] Davis ME. The first targeted delivery of siRNA in humans via a self-assembling, cyclodextrin polymer-based nanoparticle: from concept to clinic[J].Mol Pharm, 2009. 6(3): 659-668.
    [20] Hu T.N, Wang QW, Jin X, et al. Anticancer effect of triptolide-polyethylenimine-cyclodextrin in vitro[J].J Zhejiang Univ (Med Sci), 2012, 41(6): 610-619.
    [21] Boe SL, Longva AS, Hovig E. Cyclodextrin-containing polymer delivery system for light-directed siRNA gene silencing[J].Oligonucleotides, 2010, 20(4): 175-182.
    [22] Fang B, Jiang L, Zhang M,et al. A novel cell-penetrating peptide TAT-A1 delivers siRNA into tumor cells selectively[J].Biochimie, 2013, 95(2): 251-257.
    [23] Choi YS, Lee JY, Suh JS, et al. The systemic delivery of siRNAs by a cell penetrating peptide, low molecular weight protamine[J].Biomaterials, 2010, 31(6): 1429-1443.
    [24] Alberici L, Roth L, Sugahara KN, et al. De novo design of a tumor-penetrating peptide[J].Cancer Res, 2013, 73(2): 804-812.
    [25] Lin D, Cheng Q, Jiang Q, et al. Intracellular cleavable poly(2-dimethylaminoethyl methacrylate) functionalized mesoporous silica nanoparticles for efficient siRNA delivery in vitro and in vivo[J].Nanoscale, 2013.5, 4291-4301.
    [26] Li X, Chen Y, Wang M, et al. A mesoporous silica nanoparticle-PEI-fusogenic peptide system for siRNA delivery in cancer therapy[J].Biomaterials, 2013, 34(4): 1391-1401.
  • [1] 丁华敏, 郭羽晨, 秦春霞, 宋志兵, 孙莉莉.  消风止痒颗粒通过降低白三烯水平对小鼠特应性皮炎急性瘙痒的治疗作用研究 . 药学实践与服务, 2024, 42(5): 211-216. doi: 10.12206/j.issn.2097-2024.202306031
    [2] 唐淑慧, 凤美娟, 薛智霞, 鲁桂华.  帕博利珠单抗治疗所致免疫相关不良反应与中医体质的相关性研究 . 药学实践与服务, 2024, 42(5): 217-222. doi: 10.12206/j.issn.2097-2024.202311029
    [3] 景凯, 杨慈荣, 张圳, 臧艺蓓, 刘霞.  黄芪甲苷衍生物治疗慢性心力衰竭小鼠的药效评价及作用机制研究 . 药学实践与服务, 2024, 42(5): 190-197. doi: 10.12206/j.issn.2097-2024.202310004
    [4] 张晶晶, 索丽娜, 郑兆红.  89例细菌性肝脓肿的临床特征及抗感染治疗分析 . 药学实践与服务, 2024, 42(6): 267-272. doi: 10.12206/j.issn.2097-2024.202302039
    [5] 马兹芬, 许维恒, 金煜翔, 薛磊.  食管癌的靶向治疗与免疫治疗研究进展 . 药学实践与服务, 2024, 42(6): 231-237. doi: 10.12206/j.issn.2097-2024.202306008
    [6] 张成中, 朱雪艳, 卜其涛, 王宏瑞, 黄宝康.  基于网络药理学与分子对接预测鸡骨草特征图谱研究 . 药学实践与服务, 2024, 42(7): 1-9. doi: 10.12206/j.issn.2097-2024.202303048
    [7] 王雪莲, 郑斯莉, 李志勇, 罗亨宇, 缪朝玉.  全身过表达人METRNL基因小鼠模型的构建与验证 . 药学实践与服务, 2024, 42(5): 198-202, 222. doi: 10.12206/j.issn.2097-2024.202311014
    [8] 宋雨桐, 夏德润, 顾珩, 唐少文, 易洪刚, 沃红梅.  帕博利珠单抗与铂类化疗方案在晚期非小细胞肺癌一线治疗中的药物经济学评价 . 药学实践与服务, 2024, 42(7): 1-7. doi: 10.12206/j.issn.2097-2024.202303023
  • 加载中
WeChat 点击查看大图
计量
  • 文章访问数:  3088
  • HTML全文浏览量:  274
  • PDF下载量:  252
  • 被引次数: 0
出版历程
  • 收稿日期:  2014-02-21
  • 修回日期:  2015-03-05

用于肿瘤治疗的小分子干扰RNA非病毒载体研究进展

doi: 10.3969/j.issn.1006-0111.2015.06.005
  • 1. 福建中医药大学药学院, 福建 福州 350122
  • 2. 第二军医大学药学院无机化学教研室, 上海 200433
  • 收稿日期: 2014-02-21
  • 修回日期: 2015-03-05

摘要: 近年来,小分子干扰RNA(siRNA)作为RNA干扰 (RNAi) 技术的效应分子,已被广泛用于恶性肿瘤的基因治疗领域。欲获得理想的治疗效果,其关键因素是寻找一种安全、高效、稳定、可控的基因载体。非病毒载体具有低毒、低免疫原性、制备简单、目的基因容量大、外源基因随机整合率低且携带基因大小类型不受限制等突出优势,已经成为目前siRNA载体的研究热点。在以往学者的研究基础上,从药剂学的角度,笔者对这些载体在siRNA传递系统中的研究现况做回顾性总结。

English Abstract

王欢, 马志强, 杨峰. 用于肿瘤治疗的小分子干扰RNA非病毒载体研究进展[J]. 药学实践与服务, 2015, 33(6): 498-501. doi: 10.3969/j.issn.1006-0111.2015.06.005
引用本文: 王欢, 马志强, 杨峰. 用于肿瘤治疗的小分子干扰RNA非病毒载体研究进展[J]. 药学实践与服务, 2015, 33(6): 498-501. doi: 10.3969/j.issn.1006-0111.2015.06.005
shu
WANG Huan, MA Zhiqiang, YANG Feng. Current status of non-viral siRNA vectors for therapy of cancers[J]. Journal of Pharmaceutical Practice and Service, 2015, 33(6): 498-501. doi: 10.3969/j.issn.1006-0111.2015.06.005
Citation: WANG Huan, MA Zhiqiang, YANG Feng. Current status of non-viral siRNA vectors for therapy of cancers[J]. Journal of Pharmaceutical Practice and Service, 2015, 33(6): 498-501. doi: 10.3969/j.issn.1006-0111.2015.06.005
shu

    全文HTML

参考文献 (26)

目录

    /

    返回文章
    返回

    版权所有：《药学实践与服务》编辑委员会

    主管、主办: 中国人民解放军海军军医大学地址: 上海市杨浦区国和路325号邮政编码: 200433

    电话: （021）81871324,81871397 E-mail: yxsjzzs@163.com

    网站备案号 沪ICP备05003363号-1

    本系统由 北京仁和汇智信息技术有限公司 开发    百度统计